Siegfried Holding AG, commonly referred to as Siegfried, is a prominent player in the pharmaceutical and chemical industry, headquartered in Switzerland (CH). Founded in 1873, the company has established a strong presence in Europe and North America, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. Siegfried is renowned for its innovative solutions in contract development and manufacturing, catering to a diverse clientele in the pharmaceutical sector. The company’s commitment to quality and sustainability sets it apart, ensuring compliance with stringent regulatory standards. With a robust market position, Siegfried has achieved significant milestones, including strategic acquisitions that have expanded its capabilities and global reach. As a trusted partner in the pharmaceutical supply chain, Siegfried continues to drive advancements in drug development and production.
How does Siegfried Holding's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Siegfried Holding's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Siegfried Holding AG reported total carbon emissions of approximately 517,000,000 kg CO2e, comprising 59,171,000 kg CO2e from Scope 1, 12,622,000 kg CO2e from Scope 2, and 459,700,000 kg CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 emissions compared to 2023, where total emissions were approximately 730,280,000 kg CO2e, with Scope 1 at 58,411,000 kg CO2e and Scope 2 at 14,617,000 kg CO2e. Siegfried has committed to significant climate action, aiming for a 50% reduction in its Scope 1 and 2 emissions by 2030, normalised against sales, with a baseline year of 2020. Additionally, the company has set ambitious long-term targets, including achieving net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a 66.89% reduction in absolute Scope 1 and 2 emissions by 2033 from a 2020 baseline, and a 32.5% reduction in Scope 3 emissions from specific categories by 2033 from a 2022 baseline. Siegfried's climate commitments align with the Science Based Targets initiative (SBTi), demonstrating its dedication to sustainable practices within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000,000 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Siegfried Holding has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Siegfried Holding's sustainability data and climate commitments
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.